Clinical Trials Logo

Clinical Trial Summary

This laboratory study is collecting tumor tissue and blood samples from patients with gynecologic tumors. Collecting and storing samples of tumor tissue and blood from patients with cancer to study in the laboratory may help in the study of cancer.


Clinical Trial Description

PRIMARY OBJECTIVES:

I. To collect gynecologic tissue and blood from participating Gynecologic Oncology Group (GOG) institutions.

II. To provide a repository for long-term storage of gynecologic tissue and blood that will be used in studies designed to better understand the molecular biology of gynecologic tumors.

III. To make available, through the GOG Tissue Bank, tissue and blood for proposed projects conducted by GOG and non-GOG investigators.

OUTLINE:

Snap frozen tumor tissue, OCT molds of tumor tissue, formalin-preserved tumor tissue, buffy coat-prepared tumor tissue, and blood samples are collected and stored in the repository. Patient information is kept confidential, and patients are not informed of any research/test results from use of their tissues. ;


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms

  • Adenocarcinoma
  • Borderline Ovarian Clear Cell Tumor
  • Borderline Ovarian Serous Tumor
  • Brenner Tumor
  • Carcinoma
  • Carcinoma, Adenosquamous
  • Carcinoma, Small Cell
  • Carcinoma, Squamous Cell
  • Cervical Adenocarcinoma
  • Cervical Adenosquamous Carcinoma
  • Cervical Small Cell Carcinoma
  • Cervical Squamous Cell Carcinoma, Not Otherwise Specified
  • Childhood Embryonal Rhabdomyosarcoma
  • Childhood Malignant Ovarian Germ Cell Tumor
  • Cystadenocarcinoma
  • Endometrioid Stromal Sarcoma
  • Fallopian Tube Neoplasms
  • Germinoma
  • Gestational Trophoblastic Disease
  • Gestational Trophoblastic Tumor
  • Leiomyosarcoma
  • Lung Neoplasms
  • Malignant Mesothelioma
  • Malignant Ovarian Epithelial Tumor
  • Melanoma
  • Mesothelioma
  • Neoplasm of Uncertain Malignant Potential
  • Neoplasms
  • Neoplasms, Germ Cell and Embryonal
  • Ovarian Brenner Tumor
  • Ovarian Clear Cell Cystadenocarcinoma
  • Ovarian Neoplasms
  • Ovarian Serous Cystadenocarcinoma
  • Paget Disease of the Vulva
  • Peritoneal Neoplasms
  • Recurrent Cervical Carcinoma
  • Recurrent Fallopian Tube Carcinoma
  • Recurrent Ovarian Carcinoma
  • Recurrent Ovarian Germ Cell Tumor
  • Recurrent Primary Peritoneal Carcinoma
  • Recurrent Uterine Corpus Carcinoma
  • Recurrent Vaginal Carcinoma
  • Recurrent Vulvar Carcinoma
  • Rhabdomyosarcoma
  • Small Cell Lung Carcinoma
  • Stage I Ovarian Cancer
  • Stage I Uterine Corpus Cancer
  • Stage I Vaginal Cancer
  • Stage I Vulvar Cancer
  • Stage IA Cervical Cancer
  • Stage IA Fallopian Tube Cancer
  • Stage IA Ovarian Cancer
  • Stage IA Ovarian Germ Cell Tumor
  • Stage IB Cervical Cancer
  • Stage IB Fallopian Tube Cancer
  • Stage IB Ovarian Cancer
  • Stage IB Ovarian Germ Cell Tumor
  • Stage IC Fallopian Tube Cancer
  • Stage IC Ovarian Cancer
  • Stage IC Ovarian Germ Cell Tumor
  • Stage II Ovarian Cancer
  • Stage II Uterine Corpus Cancer
  • Stage II Vaginal Cancer
  • Stage II Vulvar Cancer
  • Stage IIA Cervical Cancer
  • Stage IIA Fallopian Tube Cancer
  • Stage IIA Ovarian Cancer
  • Stage IIA Ovarian Germ Cell Tumor
  • Stage IIB Cervical Cancer
  • Stage IIB Fallopian Tube Cancer
  • Stage IIB Ovarian Cancer
  • Stage IIB Ovarian Germ Cell Tumor
  • Stage IIC Fallopian Tube Cancer
  • Stage IIC Ovarian Cancer
  • Stage IIC Ovarian Germ Cell Tumor
  • Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor
  • Stage III Cervical Cancer
  • Stage III Uterine Corpus Cancer
  • Stage III Vaginal Cancer
  • Stage III Vulvar Cancer
  • Stage IIIA Fallopian Tube Cancer
  • Stage IIIA Ovarian Cancer
  • Stage IIIA Ovarian Germ Cell Tumor
  • Stage IIIA Primary Peritoneal Cancer
  • Stage IIIB Fallopian Tube Cancer
  • Stage IIIB Ovarian Cancer
  • Stage IIIB Ovarian Germ Cell Tumor
  • Stage IIIB Primary Peritoneal Cancer
  • Stage IIIC Fallopian Tube Cancer
  • Stage IIIC Ovarian Cancer
  • Stage IIIC Ovarian Germ Cell Tumor
  • Stage IIIC Primary Peritoneal Cancer
  • Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor
  • Stage IV Fallopian Tube Cancer
  • Stage IV Ovarian Cancer
  • Stage IV Primary Peritoneal Cancer
  • Stage IV Uterine Corpus Cancer
  • Stage IVA Cervical Cancer
  • Stage IVA Vaginal Cancer
  • Stage IVB Cervical Cancer
  • Stage IVB Vaginal Cancer
  • Stage IVB Vulvar Cancer
  • Trophoblastic Neoplasms
  • Uterine Cervical Neoplasms
  • Uterine Corpus Cancer
  • Uterine Corpus Leiomyosarcoma
  • Uterine Neoplasms
  • Vaginal Neoplasms
  • Vulvar Neoplasms
  • Vulvar Squamous Cell Carcinoma

NCT number NCT00897442
Study type Observational
Source Gynecologic Oncology Group
Contact
Status Completed
Phase N/A
Start date June 1992

See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT03979872 - Risk Information and Skin-cancer Education for Undergraduate Prevention N/A
Recruiting NCT04986748 - Using QPOP to Predict Treatment for Sarcomas and Melanomas
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Recruiting NCT05707286 - Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
Active, not recruiting NCT05470283 - Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma Phase 1
Recruiting NCT05077137 - A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy Phase 1
Active, not recruiting NCT02721459 - XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma Phase 1
Active, not recruiting NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Recruiting NCT05839912 - Excision of Lymph Node Trial (EXCILYNT) (Mel69) N/A
Recruiting NCT04971499 - A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma Phase 1/Phase 2
Recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05263453 - HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03348891 - TNF in Melanoma Patients Treated With Immunotherapy N/A
Completed NCT03171064 - Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment Phase 2
Not yet recruiting NCT05539118 - Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma Phase 1/Phase 2
Recruiting NCT05171374 - pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
Withdrawn NCT02854488 - Yervoy Pregnancy Surveillance Study
Completed NCT00297895 - Multicenter Selective Lymphadenectomy Trial II (MSLT-II) N/A